ANTI-PD-L1 ANTIBODIES AND FUSION PROTEINS THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Feb 29, 2024
app pub date -
Jan 6, 2022
filing date -
Jan 6, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The invention relates generally to anti-PD-L1 antibodies, and recombinant sialidase and anti-PD-L1 immunoglobulin antigen-binding domain fusion proteins. The invention also provides antibody conjugates including a sialidase and an anti-PD-L1 antibody or a portion thereof. The invention further relates to methods of using the antibodies, sialidase fusion proteins, or antibody conjugates for treating cancer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully